Arterial hypertension and stroke prevention: An update

Clinical and Experimental Hypertension

Volumn 28, Issue 3-4, 2006, Pages 317-326

  Bornstein, Natan ^a   Silvestrelli, Giorgio ^b   Caso, Valeria ^b   Parnetti, Lucilla ^b  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Arterial hypertension; Clinical trials; Stroke

Indexed keywords

AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CHLORTALIDONE; CLONIDINE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDRALAZINE; HYDROCHLOROTHIAZIDE; INDAPAMIDE; LISINOPRIL; LOSARTAN; PERINDOPRIL; PLACEBO; RAMIPRIL; RESERPINE;

ANTIHYPERTENSIVE THERAPY; ATHEROSCLEROSIS; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMPARATIVE STUDY; CONFERENCE PAPER; CONFIDENCE INTERVAL; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; FOLLOW UP; HEART INFARCTION; HUMAN; HYPERTENSION; INCIDENCE; ISCHEMIC HEART DISEASE; LIFESTYLE; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; PROPHYLAXIS; RISK ASSESSMENT; SODIUM RESTRICTION; STROKE; TRANSIENT ISCHEMIC ATTACK; BLOOD PRESSURE; CEREBROVASCULAR ACCIDENT; DRUG EFFECT; REVIEW; RISK FACTOR; TREATMENT OUTCOME;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIALS; HUMANS; HYPERTENSION; LIFE STYLE; RISK FACTORS; TREATMENT OUTCOME;

EID: 33746466716     PISSN: 10641963     EISSN: 15256006     Source Type: Journal    
DOI: 10.1080/10641960600549405     Document Type: Conference Paper

References (29)

1. Caplan LR. Stroke. Clin Symp 1988; 40(4):1-32.
2. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, et al. Blood pressure, stroke, and coronary heart disease. Part 1. Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335(8692): 765-774.
3. MacMahon S, Rodgers A. Blood pressure, antihypertensive treatment and stroke risk. J Hypertens (Suppl) 1994; 12(10):S5-14.
4. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, et al. Blood pressure, stroke, and coronary heart disease. Part 2. Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335(8693):827-838.
5. Cook NR, Cohen J, Hebert PR, Taylor JO, Hennekens CH. Implications of small reductions in diastolic blood pressure for primary prevention. Arch Intern Med 1995; 155(7):701-709.
6. Amery A, Birkenhager W, Brixko P, Bulpitt C, Clement D, Deruyttere M, et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet 1985; 1(8442):1349-1354.
7. He J, Whelton PK. Elevated systolic blood pressure and risk of cardiovascular and renal disease: overview of evidence from observational epidemiologic studies and randomized controlled trials. Am Heart J 1999; 138(3 Pt 2):211-219.
8. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-convertingenzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342(3):145-153.
9. Svensson P, de Faire U, Sleight P, Yusuf S, Ostergren J. Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE substudy. Hypertension 2001; 38(6):E28-32.
10. Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet 2001; 358(9290):1305-1315.
11. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA 2002; 288(23):2981-2997.
12. Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, et al. ALLHAT Collaborative Research Group. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich) 2002; 4(6):393-404.
13. Wing LM, Reid CM, Ryan P, Beilin LJ, Brown MA, Jennings GL, et al. Second Australian National Blood Pressure Study Group. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003; 348(7):583-592.
14. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359(9311):995-1003.
15. Dahlof B, Devereux R, de Faire U, Fyhrquist F, Hedner T, Ibsen H, et al. The Losartan Intervention For Endpoint reduction (LIFE) in hypertension study: rationale, design, and methods. The LIFE Study Group. Am J Hypertens 1997; 10(7 Pt 1):705-713.
16. Kjeldsen SE, Dahlof B, Devereux RB, Julius S, Aurup P, Edelman J, et al. LIFE (Losartan Intervention for Endpoint Reduction) Study Group. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy. JAMA 2002; 288(12):1491-1498.
17. Devereux RB, Dahlof B, Kjeldsen SE, Julius S, Aurup P, Beevers G, et al. LIFE Study Group.Effects of losartan or atenolol in hypertensive patients without clinically evident vascular disease: a substudy of the LIFE randomized trial. Ann Intern Med 2003; 139(3):169-177.
18. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353(9153):611-616.
19. Hansson L, Lindholm LH, Ekbom T, Dahlof B, Lanke J, Schersten B, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999; 354(9192):1751-1756.
20. Hansson L, Hedner T, Lund-Johansen P, Kjeldsen SE, Lindholm LH, Syvertsen JO, et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000; 356(9227):359-365.
21. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358(9287):1033-1041.
22. Chapman N, Huxley R, Anderson C, Bousser MG, Chalmers J, Colman S, et al. Writing Committee for the PROGRESS Collaborative Group. Effects of a perindopril-based blood pressure-lowering regimen on the risk of recurrent stroke according to stroke subtype and medical history: the PROGRESS Trial. Stroke 2004; 35(1):116-21. Epub 2003 Dec 11.
23. Gorelick PB. New horizons for stroke prevention: PROGRESS and HOPE. Lancet Neurol 2002; 1(3):149-156.
24. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42(6):1206-1252. Epub 2003 Dec 01.
25. He J, Whelton PK, Appel LJ, Charleston J, Klag MJ. Long-term effects of weight loss and dietary sodium reduction on incidence of hypertension. Hypertension 2000; 35(2):544-549.
26. Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, et al. DASH-Sodium Collaborative Research Group.Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. N Engl J Med 2001; 344(1):3-10.
27. Chobanian AV, Hill M. National Heart, Lung, and Blood Institute Workshop on Sodium and Blood Pressure : a critical review of current scientific evidence. Hypertension 2000; 35(4):858-863.
28. Kelley GA, Kelley KS. Progressive resistance exercise and resting blood pressure: a metaanalysis of randomized controlled trials. Hypertension 2000; 35(3):838-843.
29. Xin X, He J, Frontini MG, Ogden LG, Motsamai OI, Whelton PK. Effects of alcohol reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension 2001; 38(5):1112-1117.